中文摘要：

肿瘤分子靶向药物因其特异性强、耐受性好等特点,在肿瘤治疗中占有越来越重要的地位。分子靶向治疗药物的种类很多,包括单克隆抗体和小分子激酶抑制剂等,从1997年首个单抗药物利妥昔单抗上市到目前为止,已被批准上市的药物达50多种,抗肿瘤靶点也趋于多样化。以肿瘤细胞特异性分子靶点为导向的药物研发已经成为现代抗肿瘤药物发展的主流趋势。本文对FDA批准上市的分子靶向药物进行总结,按照作用靶点的不同进行分类,并对各类药物的分子机制及临床使用情况作一概述。

英文摘要：

Molecular target-based cancer therapy is playing a more and more important role in cancer therapy because of its high specificity, good tolerance and so on. There are different kinds of molecular targeted drugs such as monoclonal antibodies and small molecular kinase inhibitors, and more than 50 drugs have been approved since 1997. When the first monoclonal antibody, rituximab, was on the market. The development of molecular target-based cancer therapeutics has become the main approach. Based on this, we summarized the drugs approved by FDA and introduced their mechanism of actions and clinical applications. In order to incorporate most molecular targeted drugs and describe clearly various characteristics, we divided them into four categories： drugs related to EGFR, drugs related to antiangiogenesis, drugs related to specific antigen and other targeted drugs. The purpose of this review is to provide a current status of this field and discover the main problems in the molecular targeted therapy.